Subst. Form PTO-1449 APPLICANT'S(S') INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 25795-4-2	Serial No.: 09/419,517
	Applicant(s): KAESEMEYER	
	Filing Date: October 18, 1999	Group: 1614

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	FA	5,273,875	12/1993	Griffith	435	1	
	FB	5,366,738	11/1994	Rork et al.	424	473	
	FC	5,767,160	6/1998	Kaesemeyer	574	565	
	FD	5,968,983	10/1999	Kaesemeyer	514	564	

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	FE	WO 99/18952	22.04.99	International	—	—	

OTHER ART

No copies	FF	Duggan, D.E. et al ~~The Physiological Disposition of Lovastatin~~. Drug Metabolism and Disposition, ~~Vo. 17~~, No. 2. pp. 166-173. ~~1989~~.
	FG	Morris et al. An Integrated Approach to the Selection of Optimal Salt from a New Drug Candidate, International Journal of Pharmaceutic (Amsterdam), 105(3), 209-217, 1994, see abstract.
No copies	FH	Vickers, S. et al: ~~Metabolic Disposition Studies on Simvastatin, a Cholesterol-Lowering Prodrug~~. Drug Metabolism and Disposition, Vol. 18, No. 2. pp. ~~135-145~~. 1990.

Examiner: _____ Date Considered: 4/30/00

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 25795-4-2	SER. NO. 09/419,517
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	APPLICANT KAESEMEYER	
	FILING DATE October 18, 1999	GROUP ART UNIT 1614

OTHER DOCUMENTS
(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
_____	EA	Haman, M. et al. Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury. Circulation, Vol. 90. No. 3, pp. 1357-1362. September, 1994.
_____	EB	Harrison, D.G. Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis. J. Am. Coll. Cardiol. Vol. 17. pp. 71B-6B. 1991.
_____	EC	Cooke, J.P. et al. Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta. Circulation. Vol. 83. pp. 1057-1062. 1991.
_____	ED	Witzum, J.L. et al. Role of Oxidized Low Density Lipoprotein in Atherogenesis. J. Clin. Invest. Vol. 88. pp. 1785-1792. 1991.
_____	EE	Mugge, A.J. et al. Chronic Treatment with Polyethylene-Glycolated Superoxide Dismutase Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits. Circ. Res. Vol. 69. pp. 1293-1300. 1991.
_____	EF	Forstermann, U. et al. Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries. Circ. Res. Vol. 62. pp. 185-191. 1988.
_____	EG	Cohen, R.A. et al. Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia. Circ. Res. Vol. 63. pp. 903-910. 1988.
_____	EH	Schwarzacher, A.P. et al. Locak Intramural Delivery of L-Arginine Enhances Nitric Oxide Generation and Inhibit Lesion Formation After Balloon Angioplasty. Circulation, Vol. 95. No. 7. pp. 1863-1869. April 1, 1997.
_____	EI	Verbeuren, T.J. et al. Effect of Hypercholesterolemia on Vascular Reactivity in the Rabbit., I: Endothelium-Dependent and Independent Contractions and Relaxations in Isolated Arteries of Control and Hypercholesterolemic Rabbits. Circ. Res. Vol. 58. pp. 552-564. 1986.

No Copies

	DATE CONSIDERED
	11/30/02

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SER. NO.
	25795-4-2	09/419,517
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	
	KAESEMEYER	
(37 CFR 1.98(b))	FILING DATE	GROUP ART UNIT
	October 18, 1999	1614

OIPE OCT 20 2000 PATENT & TRADEMARK OFFICE

RECEIVED OCT 25 2000 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	5,543,430	Aug. 6, 1996	Kaesemeyer	514/565	
	5,428,070	Jun. 27, 1995	Cooke et al.	514/557	
	5,316,765	May 31, 1994	Folkers et al.	424/94.1	
	5,196,195	Mar. 23, 1993	Griffith	424/94.6	
	5,158,883	Oct. 27, 1992	Griffith	435/240.2	
	5,132,453	Jul. 21, 1992	Griffith	562/560	
	5,059,712	Oct. 22, 1991	Griffith	562/560	
	4,686,211	Aug. 11, 1987	Hara et al.	514/418	

OTHER DOCUMENTS
(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
	AA	Patel, J. M. et al. Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells. (Abstract Only) Free Radical Biology & Medicine. Vol. 20, No. 5. pp. 629. 1996.
	AB	Xia, Y. et al. Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury. Proc. Natl. Acad. Sci. USA. Vol. 93. pp. 6770-6774. June 1996.
no copies	AC	Jeremy, R. W. et al. Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasolidation in the Hypercholesteralemic Rabbit. Circulation. Vol. 94, No. 3. pp. 498-506. August 1, 1996.
	AD	Block, E. R. et al. Hypoxia Inhibits L-Arginine Uptake By Pulmonary Artery Endothelial Cells. (Abstract Only) Am. J. Physiol. Vol. 269. L574-L580. 1995.
	AE	Mayer, B. et al. Brain Nitric Oxide Synthase is a Biopterin-and Flavin-Containing Multi-Functional Oxido-Reductase. (Abstract Only) FEBS 10045. Vol. 288, No. 1,2. pp. 187-191. August 1991.
	AF	Weidinger, F. F. et al. Persistent Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery. Circulation. Vol. 81, No. 5. pp. 1667-1679. May 1990.

	DATE CONSIDERED
	11/30/00

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considere Include copy of this form with n xt communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 25795-4-2	SER. NO. 09/419,517
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT KAESEMEYER	
(37 CFR 1.98(b))	FILING DATE October 18, 1999	GROUP ART UNIT 1614

OTHER DOCUMENTS
(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
_____	BA	Chester, A. H. et al. Low Basal and Stimulated Release of Nitric Oxide in Atherosclerotic Epicardial Coronary Arteries. The Lancet. Vol. 336. pp. 897-900. Oct. 13, 1990.
_____	BB	Albina, J. E. et al. Arginine Metabolism in Wounds. Am. J. Physiol. Vol. 254. pp. E459-E467. 1988.
_____	BC	Cooke, J.P. et al. Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit. (Abstract Only) J. Clin. Invest. Vol. 90, No. 3. pp. 1168-72. Sep. 1992.
_____	BD	Nakamura, Y. et al. Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIga Pravastatin Study). (Abstract Only). Cardiovasc. Drugs. Ther., Vol. 10, No. 4, pp. 475-483. 1996.
_____	BE	Pohl, U. et al. Effects of LDL on Intracellular Free Calcium and Nitric Oxide-Dependent cGMP Formation on Porcine Endothelial Cells. (Abstract only) Atherosclerosis. Vol. 117. pp. 169-178. 1995.
no copies	BF	Deliconstantinos, G. et al. Modulation of Particulate Nitric Oxide Synthase Activity and Peroxynitrate Synthesis in Cholesterol Enriched Endothelial Cell Membranes. (Abstract Only) Biochem. Pharm. Vol. 49. No. 11. pp. 1589-1600. 1995.
_____	BG	Galle, J. et al. Effect of HDL and Atherogenic Lipoproteins on Formation of O_2 and Renin Release in Juxtaglomerular Cells. (Abstract Only) Kidney International. Vol. 51. pp. 253-260. 1997.
_____	BH	Bult, H. Nitric Oxide and Atherosclerosis: Possible Implications for Therapy. (Abstract only) Molecular Medicine Today. p. 510. December 1996.
_____	BI	Crouse III, J.R. et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). (Abstract only) Am. J. Cardiol. Vol. 75. pp. 455-459. 1995.
_____	BJ	Aji, W. et al. L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL Receptor Knockout Mice. (Abstract only) Circulation. Vol. 95. pp. 430-437. 1997.
_____	BK	Cooke, J. P. et al. Arginine: A new Therapy for Atherosclerosis?. Circulation. Vol. 95. pp. 311-12. 1997.
_____	BL	Boger, R. H. et al. The L-Arginine Nitric Oxide Pathway: Role in Atherosclerosis and Therapeutic Implications. (First page only) Atherosclerosis. Vol. 127. pp. 1-11. 1996.

	DATE CONSIDERED
	11/30/00

EXAMINER: Initial citation consid r d. Draw lin through citation if not in conformance and not considere Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SER. NO.
	25795-4--2	09/419,517
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT	
	KAESEMEYER	
	FILING DATE	GROUP ART UNIT
(37 CFR 1.98(b))	October 18, 1999	1614

OTHER DOCUMENTS
(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
_____	CA	Jay, M.T. et al. Modulation of Vascular Tone By Low Density Lipoproteins, Effects on L-Arginine Transport and Nitric Oxide Synthesis. Experimental Physiology. Vol. 82. pp. 349-360. 1997.
_____	CB	Muramatsu, J. et al. Hemodynamic Changes Associated with Reduction in Total Cholesterol By Treatment with the HMG-CoA Reductase Inhibitor Pravastatin. Atherosclerosis. Vol. 130. pp. 179-182. 1997.
_____	CC	Sacks, F. M. et al. The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels. The New England Journal of Medicine. Vol. 335. pp. 1001-1009. October 3, 1996.
_____	CD	Bovan, A. J. van. et al. Reduction of Transient Myocardial Ischemia with Pravastatin in Addition to the Conventional Treatment in Patients with Angina Pectoris. Circulation. Vol. 94. pp. 1503-1505. 1996.
no copies	CE	Lacoste, L. et al. Comparative Effect of Pravastatin and Simvastatin on Platelet-Thrombus Formation in Hypercholesterolemic Coronary Patients. JACC. Vol. 27 No. 2 Supp A. p. 413A. 1996.
_____	CF	Pitt, B. et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events. J. Am. Coll. Cardiol. Vol. 26. pp. 1133-9. 1995.
_____	CG	Candipan, R.C. et al. Regression or Progression: Dependency on Vascular Nitric Oxide. Arterioscler. Thromb. Vas. Biol. Vol. 16. pp. 44-50. 1996.
_____	CH	Byington, R.P. et al. Reduction in Cardiovascular Events During Pravastatin Therapy. Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program. Circulation. Vol. 92. pp. 2419-2425. 1995.
_____	CI	Pritchard, K.A. et al. Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion. Circ. Res. Vol. 77 No. 3. pp. 510-518. 1995.
_____	CJ	Boger, R.H. et al. Supplementation of Hypercholesterolemic Rabbits with L-Arginine Reduces the Vascular Release of Superoxide Anions and Restores NO Production. Artherosclerosis. Vol. 117 No. 2. pp. 273-284. 1995.

	DATE CONSIDERED
	11/30/05

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 25795-4-2	SER. NO. 09/419,517
INFORMATION DISCLOSURE STATEMENT BY APPLICANTE	APPLICANT KAESEMEYER	
(37 CFR 1.98(b))	FILING DATE October 18, 1999	GROUP ART UNIT 1614

OTHER DOCUMENTS
(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
_____	DA	Lacoste, L. et al. Correction of the Increased Thrombogenic Potential with Cholesterol Reduction. Circulation. Vol 92. pp. 3172-3177. 1995.
_____	DB	Shepard, J. Prevention of Coronary Heart Disease with Provastatin in Men with Hypercholestrolemia. The New England Journal of Medicine Vol. 333. pp. 1301-1307. November 16, 1995.
_____	DC	Philis-Tsimikas, A. et al. L-Arginine May Inhibit Atherosclerosis Through Inhibition of LDL Oxidation. Circulation. Vol. 92 (Supp. I). pp. I-422. 1995.
_____	DD	Von der Leyen, H.E. et al. Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene. Proc. Natl. Acad. Sci. USA. Vol. 92. pp. 1137-1141. 1995.
_____	DE	Egashira, K. et al. Reduction in Serum Cholesterol with Pravastatin Improves Endothelium-Dependent Coronary Vasomotion in Patients with Hypercholesterolemia. Circulation. Vol. 89. pp. 2519-2524. 1994.
No copies	DF	Tsao, P. et al. Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine. Circulation. Vol. 89. pp. 2176-2182. 1994.
_____	DG	Cayatte, A.J. et al. Chronic Inhibition of Nitric Oxide Production Accelerates Neointima Formation and Impairs Endothelial Function in Hypercholesterolemic Rabbits. Arterioscler. Thomb. Vol. 14. pp. 753-759. 1994.
_____	DH	Wilcox, J.N. et al. Expression of Multiple Nitric Oxide Synthase Isoforms in Human Aortic Fatty Streaks and Advanced Atherosclerotic Plaques. (Abstract only) Circulation. Vol. 90 (Supp. I). pp. I-298. 1994.
_____	DI	Chen, L. Y. et al. Oxidated LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function. Circulation. Vol. 93. pp. 1740-1746. 1993.
_____	DJ	Wada, H. et al. Hypercoagulable State in Patients with Hypercholesterolemia: Effects of Pravastatin. Clin. Therap. Vol. 14. pp. 829-34. 1992.
_____	DK	Dresler, H. et al. Correction of Endotelial Dysfunction in Coronary Microcirculation of Hypercholesterolaemia Patients by L-Arginine. The Lancet. Vol. 338. pp. 1546-1550. Dec. 21/28, 1991.

	DATE CONSIDERED
	11/30/00